Enanta Pharmaceuticals (ENTA) Current Deferred Revenue (2012 - 2014)

Enanta Pharmaceuticals (ENTA) has 3 years of Current Deferred Revenue data on file, last reported at $51000.0 in Q1 2014.

• For the quarter ending Q1 2014, Current Deferred Revenue fell 55.65% year-over-year to $51000.0; the trailing twelve-month figure through Mar 2014 stood at $51000.0 (down 55.65% YoY), and the FY2013 full-year result was $10000.0, down 41.18% from the prior year.
• Current Deferred Revenue for Q1 2014 stood at $51000.0, up from $5000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $115000.0 in Q1 2013 and bottomed at $5000.0 in Q4 2013.
• The 3-year median for Current Deferred Revenue is $17000.0 (2012), against an average of $39600.0.
• The widest annual swing landed in 2013, when Current Deferred Revenue slumped 41.18%; it then tumbled 55.65% in 2014.
• A 3-year view of Current Deferred Revenue shows it stood at $17000.0 in 2012, then tumbled by 70.59% to $5000.0 in 2013, then soared by 920.0% to $51000.0 in 2014.
• The last three Current Deferred Revenue figures came in at $51000.0 (Q1 2014), $5000.0 (Q4 2013), and $10000.0 (Q3 2013), per Business Quant data.

Peer Comparison